is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).
Finance Minister Hong Nam-ki said Thursday the government plans to spend 6.3 trillion won (US$5.3 billion) to support corporate facility investment in vaccine development...
Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19...
Researchers at the Tokyo Metropolitan Institute of Medical Science are working on a COVID-19 vaccine that not only delivers lifelong immunity against the SARS-CoV-2...
Binnopharm Group (part of Sistema) and Sartorius, one of the leading global manufacturers of equipment for the biopharmaceutical industry, have signed a strategic partnership...
R-Pharm Group, the Russian Direct Investment Fund (RDIF) and AstraZeneca announce preliminary virus neutralizing activity results of combined use of the AstraZeneca vaccine (developed...